# Systemic Application of Cadonilimab, LM-302, and S-1 Combined With Intraperitoneal Infusion of Paclitaxel for the Treatment of Claudin 18.2-positive Gastric Cancer With Peritoneal Metastasis

> **NCT06519591** · PHASE2 · RECRUITING · sponsor: **Ruijin Hospital** · enrollment: 40 (estimated)

## Conditions studied

- Gastric Cancer Stage IV
- Peritoneal Metastases

## Interventions

- **DRUG:** Cadonilimab, LM-302, S-1, paclitaxel

## Key facts

- **NCT ID:** NCT06519591
- **Lead sponsor:** Ruijin Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-02-25
- **Primary completion:** 2026-05
- **Final completion:** 2026-12
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2026-02-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06519591

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06519591, "Systemic Application of Cadonilimab, LM-302, and S-1 Combined With Intraperitoneal Infusion of Paclitaxel for the Treatment of Claudin 18.2-positive Gastric Cancer With Peritoneal Metastasis". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT06519591. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*